Marinus Pharmaceuticals Inc MRNS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
-
Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024
-
Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference
-
Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
-
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
-
MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
-
Marinus Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 - MRNS
-
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit Filed by Rosen Law Firm
Trading Information
- Previous Close Price
- $1.73
- Day Range
- $1.71–1.82
- 52-Week Range
- $1.05–11.26
- Bid/Ask
- $1.70 / $1.77
- Market Cap
- $98.05 Mil
- Volume/Avg
- 344,571 / 550,204
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.30
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 166
- Website
- https://www.marinuspharma.com
Comparables
Valuation
|
Metric
|
MRNS
|
PLRX
|
TERN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 1.77 | 2.66 |
Price/Sales | 3.30 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
MRNS
PLRX
TERN
Financial Strength
|
Metric
|
MRNS
|
PLRX
|
TERN
|
|---|---|---|---|
Quick Ratio | 1.90 | 14.21 | 20.57 |
Current Ratio | 2.28 | 14.47 | 21.02 |
Interest Coverage | −7.88 | −106.49 | — |
Quick Ratio
MRNS
PLRX
TERN
Profitability
|
Metric
|
MRNS
|
PLRX
|
TERN
|
|---|---|---|---|
Return on Assets (Normalized) | −80.57% | −27.65% | −28.87% |
Return on Equity (Normalized) | −990.50% | −31.11% | −30.36% |
Return on Invested Capital (Normalized) | −139.67% | −33.69% | −34.37% |
Return on Assets
MRNS
PLRX
TERN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Xqfxrbtg | Qxpt | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jfxjjmzss | Blcnyt | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rjfwnxv | Jylwcfp | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Smksjsh | Pkyvr | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Nswzzphpv | Cmjn | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Xtgtlrr | Xqvs | $29.2 Bil | |||
| Moderna Inc
MRNA
| Hfytxmljd | Gyjr | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Rldpclkxh | Xcdp | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gpzrbjzx | Xrmvlq | $13.2 Bil | |||
| Incyte Corp
INCY
| Ysbqvnhyj | Ppkgj | $13.0 Bil |
United States